前列腺动脉栓塞术作为前列腺增大未治疗男性一线治疗对比药物治疗的随机对照试验(P-EASY ADVANCE):前列腺动脉栓塞术与药物治疗良性前列腺增生的随机对照试验
P-EASY ADVANCE随机对照试验纳入39例未治疗的前列腺增大、中重度下尿路症状且尿动力学检查提示梗阻或可疑梗阻的男性,比较前列腺动脉栓塞术(PAE)与坦索罗辛联合度他雄胺药物治疗。PAE组解除梗阻比例高于药物组(63% vs 28%,P=0.03),前列腺体积、IPSS总分、Qmax及生活质量改善更显著;作者认为PAE可能作为早期替代治疗选择,并计划进一步随机对照试验验证。
要点
- PAE组解除梗阻比例63% vs 药物组28%(P=0.03)。
- PAE组前列腺体积缩小、IPSS总分、Qmax及生活质量改善均显著优于药物组。
- 射精改变、勃起功能障碍和恶心在药物组更常见。
核心结论
- 对于既往未接受治疗的良性前列腺增生患者,前列腺动脉栓塞术在减轻尿路梗阻、缩小前列腺体积和改善下尿路症状方面比联合药物治疗更有效。
- 这是首个仅在未治疗患者中比较PAE与联合药物治疗的随机对照研究,提示PAE可能作为良性前列腺增生的早期替代治疗选择。
- 计划进一步开展随机对照试验以验证PAE在缓解梗阻性良性前列腺增生中的作用。
研究设计与样本
- 随机对照试验,共纳入39例前列腺增大、中重度下尿路症状且尿动力学检查提示梗阻或可疑梗阻、既往未接受良性前列腺增生治疗的男性。
- 受试者随机接受坦索罗辛联合度他雄胺的联合药物治疗或前列腺动脉栓塞术。
- 干预后短期至中期随访行尿动力学检查、国际前列腺症状评分、尿流率测定和超声,并与基线比较。
主要发现
- 药物组与PAE组基线特征相似:前列腺体积分别为87.8 mL和85.4 mL,最大尿流率(Qmax)分别为6.5 mL/s和6.6 mL/s,IPSS分别为19.5和21,尿动力学检查提示梗阻者分别占79%和74%。
- 两种干预均较基线改善排尿和膀胱流出道梗阻,PAE组解除梗阻者63% vs 药物组28%(P=0.03)。
- PAE组前列腺体积缩小(P<0.001)、排尿不尽(P=0.002)、IPSS总分(P=0.032)、Qmax(P=0.006)及生活质量(P=0.001)的改善均显著大于药物组。
- 射精改变、勃起功能障碍和恶心在药物组更常见。
临床怎么用
- 作者认为PAE可能作为未治疗良性前列腺增生患者的早期替代治疗选择。
- 计划进一步开展随机对照试验以验证PAE在缓解梗阻性良性前列腺增生中的作用。
局限性
- 进一步随机对照试验尚在计划中,以进一步验证PAE在缓解梗阻性良性前列腺增生中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare prostate artery embolisation (PAE) to the combination of tamsulosin and dutasteride therapy as a potential first-line therapy for obstructive benign prostatic hyperplasia (BPH) in treatment-naïve patients in the 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE). PATIENTS AND METHODS: A total of 39 men with enlarged prostates, moderate-severe lower urinary tract symptoms (LUTS) and obstructed/equivocal urodynamic studies (UDS), and who had no prior treatment for BPH, were randomised to receive either combined medical therapy with tamsulosin and dutasteride (medication) or PAE. Follow-up UDS, International Prostate Symptom Score (IPSS), uroflowmetry and ultrasound were performed at short- to medium-term intervals following interventions and compared to baseline. RESULTS: The medication and PAE treatment groups had similar baseline characteristics, including prostate volumes (87.8 and 85.4 mL respectively), maximum urinary flow rate (Qmax; 6.5 and 6.6 mL/s, respectively), IPSS (19.5 and 21, respectively) and obstructed UDS (79% and 74%, respectively). Both interventions improved voiding and bladder outflow obstruction from baseline, with more patients unobstructed after PAE (63%) compared to medication (28%) (P = 0.03). PAE patients had significantly greater reductions in prostate size (P < 0.001), incomplete emptying (P = 0.002), total IPSS (P = 0.032), Qmax (P = 0.006) and quality of life (P = 0.001). Altered ejaculation, erectile dysfunction and nausea were more common in the medication group. CONCLUSION: Prostate artery embolisation was more effective than combined medical therapy at reducing urinary obstruction, decreasing prostate volume and improving LUTS in patients with BPH who had not previously been treated. This is the first randomised control study to compare PAE and combined medical therapy in exclusively treatment-naïve patients and raises the potential of PAE as an alternative early treatment option for BPH. Further randomised comparative trials are planned to further validate the role of PAE in mitigating obstructive BPH.
引用
- Brown N, Kiosoglous A, Castree S, et al. The 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH. BJU Int. 2024. PMID: 39139009. doi:10.1111/bju.16479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。